The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome
Open accessAbstract
Purpose: Medulloblastomas are heterogeneous tumors that collectively represent the most common malignant brain tumor in children. To understand the molecular characteristics underlying their heterogeneity and to identify whether such characteristics represent risk factors for patients with this disease, we performed an integrated genomic analysis of a large series of primary tumors. Patients and Methods: We profiled the mRNA transcriptome of 194 medulloblastomas and performed high-density single nucleotide polymorphism array and miRNA analysis on 115 and 98 of these, respectively. Non-negative matrix factorization–based clustering of mRNA expression data was used to identify molecular subgroups of medulloblastoma; DNA copy number, miRNA profiles, and clinical outcomes were analyzed for each. We additionally validated our findings in three previously published independent medulloblastoma data sets. Results: Identified are six molecular subgroups of medulloblastoma, each with a unique combination of numerical and structural chromosomal aberrations that globally influence mRNA and miRNA expression. We reveal the relative contribution of each subgroup to clinical outcome as a whole and show that a previously unidentified molecular subgroup, characterized genetically by c-MYC copy number gains and transcriptionally by enrichment of photoreceptor pathways and increased miR-183∼96∼182 expression, is associated with significantly lower rates of event-free and overall survivals. Conclusion: Our results detail the complex genomic heterogeneity of medulloblastomas and identify a previously unrecognized molecular subgroup with poor clinical outcome for which more effective therapeutic strategies should be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Self-citationSilhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Self-citationMicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
Prediction of central nervous system embryonal tumour outcome based on gene expression
Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y. H., Goumnerova, L. C., Black, P. M., Lau, C., et al. (2002) · Nature · doi:10.1038/415436a · Cited by 2,371
Self-citation
Cited by
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Self-citationMolecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
“Some recent series [28], but not others [7] have found a preponderance of females among Shh medulloblastoma.”
BackgroundResultInfluentialSelf-citationIntertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
“Prior reports have recognized the existence of additional substructure within the four consensus subgroups, particularly within groups 3 and 4 (Cho et al., 2011).”
Self-citationThe whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112
“Notable similarities between Group 3 and Group 4 have been discussed, including ambiguous cases that exhibit features characteristic of either subgroup 33–35 .”
Self-citationKool, M., Korshunov, A., Remke, M., Jones, D. T. W., Schlanstein, M., Northcott, P. A., Cho, Y.-J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0958-8 · Cited by 1,056
Self-citationSubgroup-specific structural variation across 1,000 medulloblastoma genomes
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Sorana Morrissy, A., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012) · Nature · doi:10.1038/nature11327 · Cited by 899
Self-citationRausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Self-citationMedulloblastoma exome sequencing uncovers subtype-specific somatic mutations
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012) · Nature · doi:10.1038/nature11329 · Cited by 750
Self-citationMedulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663
Self-citationRisk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1569-6 · Cited by 654
Self-citationNorthcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Self-citationStem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
Northcott, P. A., Lee, C., Zichner, T., Stütz, A. M., Erkek, S., Kawauchi, D., Shih, D. J. H., Hovestadt, V., Zapatka, M., Sturm, D., et al. (2014) · Nature · doi:10.1038/nature13379 · Cited by 642
Self-citationMedulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups
Ellison, D. W., Dalton, J., Kocak, M., Nicholson, S. L., Fraga, C., Neale, G., Kenney, A. M., Brat, D. J., Perry, A., Yong, W. H., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0800-8 · Cited by 563
Self-citationSchwalbe, E. C., Lindsey, J. C., Nakjang, S., Crosier, S., Smith, A. J., Hicks, D., Rafiee, G., Hill, R. M., Iliasova, A., Stone, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30243-7 · Cited by 516
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J. H., Martin, D. C., Castelo-Branco, P., Baskin, B., Ray, P. N., Bouffet, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5052 · Cited by 485
Self-citationDecoding the regulatory landscape of medulloblastoma using DNA methylation sequencing
Hovestadt, V., Jones, D. T. W., Picelli, S., Wang, W., Kool, M., Northcott, P. A., Sultan, M., Stachurski, K., Ryzhova, M., Warnatz, H.-J., et al. (2014) · Nature · doi:10.1038/nature13268 · Cited by 450
Self-citationGholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2968 · Cited by 426
Self-citationResolving medulloblastoma cellular architecture by single-cell genomics
Hovestadt, V., Smith, K. S., Bihannic, L., Filbin, M. G., Shaw, M. L., Baumgartner, A., DeWitt, J. C., Groves, A., Mayr, L., Weisman, H. R., et al. (2019) · Nature · doi:10.1038/s41586-019-1434-6 · Cited by 402
Self-citationRapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples
Northcott, P. A., Shih, D. J. H., Remke, M., Cho, Y.-J., Kool, M., Hawkins, C., Eberhart, C. G., Dubuc, A., Guettouche, T., Cardentey, Y., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0899-7 · Cited by 382
Self-citationActive medulloblastoma enhancers reveal subgroup-specific cellular origins
Lin, C. Y., Erkek, S., Tong, Y., Yin, L., Federation, A. J., Zapatka, M., Haldipur, P., Kawauchi, D., Risch, T., Warnatz, H.-J., et al. (2016) · Nature · doi:10.1038/nature16546 · Cited by 380
Self-citationBET Bromodomain Inhibition of MYC -Amplified Medulloblastoma
Bandopadhayay, P., Bergthold, G., Nguyen, B., Schubert, S., Gholamin, S., Tang, Y., Bolin, S., Schumacher, S. E., Zeid, R., Masoud, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2281 · Cited by 352
Self-citationKim, J., Aftab, B. T., Tang, J. Y., Kim, D., Lee, A. H., Rezaee, M., Kim, J., Chen, B., King, E. M., Borodovsky, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.017 · Cited by 346
Divergent clonal selection dominates medulloblastoma at recurrence
Morrissy, A. S., Garzia, L., Shih, D. J. H., Zuyderduyn, S., Huang, X., Skowron, P., Remke, M., Cavalli, F. M. G., Ramaswamy, V., Lindsay, P. E., et al. (2016) · Nature · doi:10.1038/nature16478 · Cited by 334
Self-citationThe clinical implications of medulloblastoma subgroups
Northcott, P. A., Korshunov, A., Pfister, S. M., & Taylor, M. D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.78 · Cited by 328
MRI Surrogates for Molecular Subgroups of Medulloblastoma
Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., et al. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3990 · Cited by 328
Self-citationAn Animal Model of MYC-Driven Medulloblastoma
Pei, Y., Moore, C. E., Wang, J., Tewari, A. K., Eroshkin, A., Cho, Y.-J., Witt, H., Korshunov, A., Read, T.-A., Sun, J. L., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.021 · Cited by 320
Self-citationEpigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., Bergthold, G., Masoud, S., Nguyen, B., Vue, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3613 · Cited by 314
Self-citationCytogenetic Prognostication Within Medulloblastoma Subgroups
Shih, D. J. H., Northcott, P. A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9539 · Cited by 313
Self-citationSharma, T., Schwalbe, E. C., Williamson, D., Sill, M., Hovestadt, V., Mynarek, M., Rutkowski, S., Robinson, G. W., Gajjar, A., Cavalli, F., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02020-0 · Cited by 310
Self-citationA Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma
Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelstein, D., Qu, C., Pounds, S., Ellison, D. W., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.023 · Cited by 305
Self-citationMedulloblastomics revisited: biological and clinical insights from thousands of patients
Hovestadt, V., Ayrault, O., Swartling, F. J., Robinson, G. W., Pfister, S. M., & Northcott, P. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0223-8 · Cited by 271
Chen, P., Fan, Y., Man, T.-K., Hung, Y., Lau, C. C., & Wong, S. T. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s18-s1 · Cited by 287
Self-citationTumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Goodspeed, A., Heiser, L. M., Gray, J. W., & Costello, J. C. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 276
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
Pei, Y., Liu, K.-W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., Maier, D. L., Udaka, Y. T., Murad, N., Morrissy, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.011 · Cited by 276
Self-citationJuraschka, K., & Taylor, M. D. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2019.5.peds18381 · Cited by 275
Adult Medulloblastoma Comprises Three Major Molecular Variants
Remke, M., Hielscher, T., Northcott, P. A., Witt, H., Ryzhova, M., Wittmann, A., Benner, A., von Deimling, A., Scheurlen, W., Perry, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9373 · Cited by 258
Michalski, J. M., Janss, A. J., Vezina, L. G., Smith, K. S., Billups, C. A., Burger, P. C., Embry, L. M., Cullen, P. L., Hardy, K. K., Pomeroy, S. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02730 · Cited by 215
“The WHO currently recognizes at least four distinct molecular subgroups of MB (ie, Wingless [WNT], Sonic Hedgehog [SHH], group 3, and group 4)(15) that exhibit divergent genetics, demographics, clinical behaviors, and prognoses.(16-19) Using conventional genomic profiling, the outcomes of ACNS0331 were contextualized…”
BackgroundResultSelf-citationRole of MYC in medulloblastoma
Roussel, M. F., & Robinson, G. W. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014308 · Cited by 180
“Group 3 medulloblastomas have the worst overall survival at ,50% survival on many protocols (Cho et al. 2011; Northcott et al. 2011; Taylor et al. 2012).”
BackgroundInfluentialTERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Remke, M., Ramaswamy, V., Peacock, J., Shih, D. J. H., Koelsche, C., Northcott, P. A., Hill, N., Cavalli, F. M. G., Kool, M., Wang, X., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1198-2 · Cited by 164
Self-citationLeary, S. E. S., Packer, R. J., Li, Y., Billups, C. A., Smith, K. S., Jaju, A., Heier, L., Burger, P., Walsh, K., Han, Y., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2224 · Cited by 164
Self-citationA first-generation pediatric cancer dependency map
Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153
Self-citationMedulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies
Wang, J., Garancher, A., Ramaswamy, V., & Wechsler-Reya, R. J. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-013838 · Cited by 113
Williamson, D., Schwalbe, E. C., Hicks, D., Aldinger, K. A., Lindsey, J. C., Crosier, S., Richardson, S., Goddard, J., Hill, R. M., Castle, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111162 · Cited by 87
Shimada, I. S., Hwang, S.-H., Somatilaka, B. N., Wang, X., Skowron, P., Kim, J., Kim, M., Shelton, J. M., Rajaram, V., Xuan, Z., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.018 · Cited by 52
PCDH10 is a candidate tumour suppressor gene in medulloblastoma
Bertrand, K. C., Mack, S. C., Northcott, P. A., Garzia, L., Dubuc, A., Pfister, S. M., Rutka, J. T., Weiss, W. A., & Taylor, M. D. (2011) · Child's Nervous System · doi:10.1007/s00381-011-1486-x · Cited by 55
Bagchi, A., Dhanda, S. K., Dunphy, P., Sioson, E., & Robinson, G. W. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7024 · Cited by 28
Genovesi, L. A., Anderson, D., Carter, K. W., Giles, K. M., & Dallas, P. B. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-507 · Cited by 23
Kameda-Smith, M. M., Zhu, H., Luo, E.-C., Suk, Y., Xella, A., Yee, B., Chokshi, C., Xing, S., Tan, F., Fox, R. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35118-3 · Cited by 7
Metadata
- Authors
- Cho, Y.-J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., Lau, C. C., Olson, J. M., Gilbertson, R. J., Gajjar, A., Delattre, O., Kool, M., Ligon, K., Meyerson, M., Mesirov, J. P., & Pomeroy, S. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-04-10
- Volume
- 29
- Issue
- 11
- Pages
- 1424-1430
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154951934
- Cited by
- 717
- References
- 36
- FWCI
- 22.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.